Replies to post #165064 on Biotech Values

[DewDiligence]

XOMA—I don't think I agree with the orphan-drug strategy, if this had any bearing on delays tacit or otherwise…

We’re on the same wavelength. Behçet’s is not a strong enough indication to be the centerpiece of the company’s business model.

[iwfal]

XOMA -

I don't think I agree with the orphan drug strategy, if this had any bearing on delays tacit or otherwise, with Adalimumab VISUAL trials underway.

FWIW I was intentionally only indirectly linking two thoughts (behcets only & pursuit of orphan) because I too doubt that they would entirely pre-plan for this result. However I do think the two thoughts might be more indirectly linked in some way - e.g. at the very least the decision to file with Behcets instead of waiting for another trial might be by-intent.

[iwfal]

XOMA - A correction:

Quote (iwfal):
Finally note that previously I commented on their late schedule pop for osteo. Apparently a pattern.


Hirogen: A good calibration point on their forthrightness and/or clinical operational management.

My above quote "apparently a pattern" was too quickly written. Having listened to the cc, yes, they have a few smaller issues with clinical operational planning - e.g. they were a little surprised by the uncommonness of the enrollees they are looking for. But the boatload of data they provided makes it clear that overall they are executing well - and learning. The bigger problem is largely beyond their control since it is about their partner's having problems opening trial sites. Of course for investors at this instant it doesn't matter too much who caused the problem.

BTW - I will document the major points of the cc at some point, but don't have time right now because it was more packed with data than I have time for at this instant.